Loading...

Understanding Antibody-Drug Conjugates (ADCs)
Learn more
ADCs are a new type of medicine that link an antibody with chemotherapy.
How to Get Into the Brain
Watch Now03:23
Ryan Watts and Mark Dennis explain how they found a new way to get medicines through the blood-brain barrier.
Journeys: Michelle Aguayo
Watch Now01:50
Michelle Aguayo shares how caring for patients led to her work at Genentech Access Solutions, where she helps patients get the medicines they need, regardless of their ability to pay.

What's New

Now available: Videos & infographics for new #Genentech medicine for HER2+ #metastatic #breastcancer bit.ly/XQq38b

FDA Approval: New #Genentech personalized medicine for HER2+ #metastatic #breastcancer. Read our release bit.ly/YhlFTE

on 02/22/2013 via Twitter

Breaking news: @US_FDA approves new type of personalized medicine in HER2+ #metastatic #breastcancer 1.usa.gov/XQmgru

on 02/22/2013 via Twitter

Looking forward to it! MT @ASCO: This year's #ASCO13 Annual Meeting theme is "Building Bridges to Conquer Cancer." ow.ly/hVGio

on 02/21/2013 via Twitter

Did you know? Women are more likely to get age-related macular degeneration (#AMD) than men. Risk factors: bit.ly/Uzz1dZ

on 02/21/2013 via Twitter

The leading cause of #blindness in people 60+ is age-related macular degeneration (#AMD). Learn how it’s detected: bit.ly/YkPLnl

on 02/18/2013 via Twitter

It’s #AMD (age-related macular degeneration) #Awareness Month. Love your eyes & get informed bit.ly/YkPLnl

on 02/15/2013 via Twitter

We're in #nerdlove with all of these women pioneers. Thanks for sharing @smithsonian! bit.ly/XzRTW5

on 02/14/2013 via Twitter

Science is always better w/ a lab partner. RT & let your #nerdlove show. bit.ly/Ygwcwl | bit.ly/XByCni

on 02/14/2013 via Twitter

RT @rleuty_biotech: FierceBiotech's 25 most influential people, incl @genentech's Hal Barron, Onyx's Tony Coles, Gilead's John Martin --...

on 02/13/2013 via Twitter

Sometimes you just need to shake things up.

Shuffle Featured

FDA Approval: New Medicine for HER2-Positive Metastatic Breast Cancer

On February 22, 2013, the FDA approved a new personalized Genentech medicine for people with an aggressive form of breast cancer.

FDA Approval: New Use of Medicine

On January 23, 2013, a Genentech medicine received FDA approval for a new use in metastatic colorectal cancer.

Patient Access

Genentech is committed to ensuring price is not a barrier to access for patients.

Understanding Biomarkers

Jeff Settleman explains how biomarkers identify which patients may benefit from certain treatments.

Press Release

(February 22, 2013) FDA Approves Genentech’s Kadcyla (ado-trastuzumab emtansine), the First Antibody-Drug Conjugate for Treating HER2-Positive Metastatic Breast Cancer

Find a Job

We're looking for smart, passionate people to join our team. Search our open positions.

Press Statement

Important information regarding counterfeit drug labeled as Altuzan (bevacizumab).

Our Pipeline

Our pipeline includes over 30 new molecular entities that address serious unmet medical needs.

Our Medicines

Prescribing information, important safety information and patient resources.

Work Life

Our people love working here, and it shows.

Inside & Out: Mark Helton

Mark Helton talks about how working at Genentech gives him a sense of purpose.

FORTUNE Best Company

We've been named to FORTUNE's "100 Best Companies to Work For" list for the 15th year in a row.